Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
HOUSTON, TEXAS, Dec. 18, 2023 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq:NXL; NXLIW) today reported the results of a study in patients with treatment-resistant depression (TRD), concerning the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, which indicated a substantial and statistically significant benefit in patients.
Related news for (NXL)
- Closing Bell Spotlight: Momentum Names from Yesterday Continue to Roar
- Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
- Breaking News: MoBot’s Latest Update as of 10/08/25 08:00 AM
- 24/7 Market News Snapshot 08 October, 2025 – Nexalin Technology, Inc. Common Stock (NASDAQ:NXL)
- MoBot alert highlights: NASDAQ: HTCR, NASDAQ: CGTX, NASDAQ: NXL, NASDAQ: ANTE, NASDAQ: MODV (08/22/25 12:00 PM)
